Kevin C Tang - Net Worth and Insider Trading

Kevin C Tang Net Worth

The estimated net worth of Kevin C Tang is at least $133 Million dollars as of 2024-10-09. Kevin C Tang is the Director, 10% Owner of La Jolla Pharmaceutical Co and owns about 9,607,934 shares of La Jolla Pharmaceutical Co (LJPC) stock worth over $60 Million. Kevin C Tang is the CEO, 10% Owner of Odonate Inc and owns about 1,277 shares of Odonate Inc (ODTC) stock worth over $22 Million. Kevin C Tang is also the 10% Owner of Vanda Pharmaceuticals Inc and owns about 2,715,852 shares of Vanda Pharmaceuticals Inc (VNDA) stock worth over $12 Million. Besides these, Kevin C Tang also holds Heron Therapeutics Inc (HRTX) , Jounce Therapeutics Inc (JNCE) , TCR2 Therapeutics Inc (TCRR) , Singular Genomics Systems Inc (OMIC) , Rain Oncology Inc (RAIN) , Assertio Holdings Inc (ASRT) , Aradigm Corp (ARDMQ) , Cyclacel Pharmaceuticals Inc (CYCC) , Aptevo Therapeutics Inc (APVO) . Details can be seen in Kevin C Tang's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Kevin C Tang has not made any transactions after 2024-09-18 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Kevin C Tang

Kevin C Tang Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Kevin C Tang owns 12 companies in total, including Odonate Inc (ODTC) , La Jolla Pharmaceutical Co (LJPC) , and Heron Therapeutics Inc (HRTX) among others .

Click here to see the complete history of Kevin C Tang’s form 4 insider trades.

Insider Ownership Summary of Kevin C Tang

Ticker	Comapny	Transaction Date	Type of Owner
ODTC	Odonate Inc	2021-11-19	director & 10 percent owner & Chief Executive Officer
LJPC	La Jolla Pharmaceutical Co	2022-08-22	director & 10 percent owner
HRTX	Heron Therapeutics Inc	2019-10-04	10 percent owner
		2017-02-23	10 percent owner
		2013-09-19	10 percent owner
		2010-01-14	10 percent owner
		2008-10-21	10 percent owner
		2006-08-11	10 percent owner
		2021-11-23	10 percent owner
		2023-03-14	10 percent owner
		2023-05-25	10 percent owner
		2023-12-18	10 percent owner

Kevin C Tang Latest Holdings Summary

Kevin C Tang currently owns a total of 12 stocks. Among these stocks, Kevin C Tang owns 9,607,934 shares of La Jolla Pharmaceutical Co (LJPC) as of December 1, 2021, with a value of $60 Million and a weighting of 45.01%. Kevin C Tang owns 1,277 shares of Odonate Inc (ODTC) as of November 19, 2021, with a value of $22 Million and a weighting of 16.4%. Kevin C Tang also owns 2,715,852 shares of Vanda Pharmaceuticals Inc (VNDA) as of January 14, 2010, with a value of $12 Million and a weighting of 9.18%. The other 9 stocks Heron Therapeutics Inc (HRTX) , Jounce Therapeutics Inc (JNCE) , TCR2 Therapeutics Inc (TCRR) , Singular Genomics Systems Inc (OMIC) , Rain Oncology Inc (RAIN) , Assertio Holdings Inc (ASRT) , Aradigm Corp (ARDMQ) , Cyclacel Pharmaceuticals Inc (CYCC) , Aptevo Therapeutics Inc (APVO) have a combined weighting of 29.4% among all his current holdings.

Latest Holdings of Kevin C Tang

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
LJPC	La Jolla Pharmaceutical Co	2021-12-01	9,607,934	6.22	59,761,349
ODTC	Odonate Inc	2021-11-19	1,277	17,050.00	21,772,850
VNDA	Vanda Pharmaceuticals Inc	2010-01-14	2,715,852	4.49	12,194,175
HRTX	Heron Therapeutics Inc	2019-10-04	5,821,098	1.93	11,205,614
JNCE	Jounce Therapeutics Inc	2023-03-14	5,300,087	1.88	9,964,164
TCRR	TCR2 Therapeutics Inc	2023-05-25	4,394,800	1.48	6,504,304
OMIC	Singular Genomics Systems Inc	2024-09-18	372,000	15.17	5,643,240
RAIN	Rain Oncology Inc	2023-12-18	3,850,513	1.21	4,659,121
ASRT	Assertio Holdings Inc	2008-01-18	954,400	1.10	1,049,840
ARDMQ	Aradigm Corp	2007-01-25	146,250	0.05	6,728
CYCC	Cyclacel Pharmaceuticals Inc	2017-02-23	1,866	0.89	1,661
APVO	Aptevo Therapeutics Inc	2021-11-23	0	0.15	0

Holding Weightings of Kevin C Tang

Kevin C Tang Form 4 Trading Tracker

According to the SEC Form 4 filings, Kevin C Tang has made a total of 7 transactions in La Jolla Pharmaceutical Co (LJPC) over the past 5 years, including 6 buys and 1 sells. The most-recent trade in La Jolla Pharmaceutical Co is the sale of 441,290 shares on December 1, 2021, which brought Kevin C Tang around $2 Million.

According to the SEC Form 4 filings, Kevin C Tang has made a total of 4 transactions in Odonate Inc (ODTC) over the past 5 years, including 3 buys and 1 sells. The most-recent trade in Odonate Inc is the sale of 275 shares on November 19, 2021, which brought Kevin C Tang around $6 Million.

According to the SEC Form 4 filings, Kevin C Tang has made a total of 0 transactions in Vanda Pharmaceuticals Inc (VNDA) over the past 5 years. The most-recent trade in Vanda Pharmaceuticals Inc is the sale of 54,900 shares on January 14, 2010, which brought Kevin C Tang around $589,077.

More details on Kevin C Tang's insider transactions can be found in the Insider Trading History of Kevin C Tang table.

Insider Trading History of Kevin C Tang

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Kevin C Tang Trading Performance

GuruFocus tracks the stock performance after each of Kevin C Tang's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Kevin C Tang is 3.26%. GuruFocus also compares Kevin C Tang's trading performance to market benchmark return within the same time period. The performance of stocks bought by Kevin C Tang within 3 months outperforms 35 times out of 63 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Kevin C Tang's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Kevin C Tang

Average Return

Average return per transaction

Outperforming Transactions

33 out of 61 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	3.14
Relative Return to S&P 500(%)	4

Kevin C Tang Ownership Network

Ownership Network List of Kevin C Tang

No Data

Ownership Network Relation of Kevin C Tang

Kevin C Tang Owned Company Details

What does Odonate Inc do?

Who are the key executives at Odonate Inc?

Kevin C Tang is the director & 10 percent owner & Chief Executive Officer of Odonate Inc. Other key executives at Odonate Inc include 10 percent owner Ecor1 Capital, Llc , director & 10 percent owner Boxer Capital, Llc , and director & 10 percent owner Aaron I. Davis .

Odonate Inc (ODTC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Odonate Inc (ODTC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Odonate Inc (ODTC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Odonate Inc (ODTC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Odonate Inc Insider Transactions

No Available Data

What does La Jolla Pharmaceutical Co do?

Who are the key executives at La Jolla Pharmaceutical Co?

Kevin C Tang is the director & 10 percent owner of La Jolla Pharmaceutical Co. Other key executives at La Jolla Pharmaceutical Co include Chief Financial Officer Michael S Hearne , director & Chief Executive Officer Larry G. Edwards , and Chief Commercial Officer Darryl Wellinghoff .

La Jolla Pharmaceutical Co (LJPC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of La Jolla Pharmaceutical Co (LJPC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of La Jolla Pharmaceutical Co (LJPC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

La Jolla Pharmaceutical Co (LJPC)'s detailed insider trading history can be found in Insider Trading Tracker table.

La Jolla Pharmaceutical Co Insider Transactions

No Available Data

What does Heron Therapeutics Inc do?

Who are the key executives at Heron Therapeutics Inc?

Kevin C Tang is the 10 percent owner of Heron Therapeutics Inc. Other key executives at Heron Therapeutics Inc include EVP & Chief Development Officer William P Forbes , other: See Footnote 2 Adam Morgan , and EVP & Chief Financial Officer Ira Duarte .

Heron Therapeutics Inc (HRTX) Insider Trades Summary

Over the past 18 months, Kevin C Tang made no insider transaction in Heron Therapeutics Inc (HRTX). Other recent insider transactions involving Heron Therapeutics Inc (HRTX) include a net purchase of 2,486,744 shares made by Adam Morgan , and a net purchase of 50,000 shares made by William P Forbes .

In summary, during the past 3 months, insiders sold 0 shares of Heron Therapeutics Inc (HRTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Heron Therapeutics Inc (HRTX) were sold and 2,536,744 shares were bought by its insiders, resulting in a net purchase of 2,536,744 shares.

Heron Therapeutics Inc (HRTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Heron Therapeutics Inc Insider Transactions

No Available Data

What does Cyclacel Pharmaceuticals Inc do?

Who are the key executives at Cyclacel Pharmaceuticals Inc?

Kevin C Tang is the 10 percent owner of Cyclacel Pharmaceuticals Inc. Other key executives at Cyclacel Pharmaceuticals Inc include director & President & C.E.O. Spiro Rombotis , director & E.V.P. & Finance & C.O.O. Paul Mcbarron , and Chief Medical Officer Mark Kirschbaum .

Cyclacel Pharmaceuticals Inc (CYCC) Insider Trades Summary

Over the past 18 months, Kevin C Tang made no insider transaction in Cyclacel Pharmaceuticals Inc (CYCC). Other recent insider transactions involving Cyclacel Pharmaceuticals Inc (CYCC) include a net purchase of 6,070 shares made by Spiro Rombotis , and a net purchase of 1,886 shares made by Paul Mcbarron .

In summary, during the past 3 months, insiders sold 0 shares of Cyclacel Pharmaceuticals Inc (CYCC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cyclacel Pharmaceuticals Inc (CYCC) were sold and 7,956 shares were bought by its insiders, resulting in a net purchase of 7,956 shares.

Cyclacel Pharmaceuticals Inc (CYCC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cyclacel Pharmaceuticals Inc Insider Transactions

No Available Data

What does Mirati Therapeutics Inc do?

Who are the key executives at Mirati Therapeutics Inc?

Kevin C Tang is the 10 percent owner of Mirati Therapeutics Inc. Other key executives at Mirati Therapeutics Inc include EVP & Chief Commercial Officer Benjamin Hickey , Sr. Vice President & Chief Scie Jamie Christensen , and Interim CFO Aaron Ondrey .

Mirati Therapeutics Inc (MRTX) Insider Trades Summary

Over the past 18 months, Kevin C Tang made no insider transaction in Mirati Therapeutics Inc (MRTX). Other recent insider transactions involving Mirati Therapeutics Inc (MRTX) include a net sale of 8,522 shares made by Jamie Christensen , a net sale of 5,907 shares made by Benjamin Hickey , and a net purchase of 2,517,946 shares made by Boxer Capital, Llc .

In summary, during the past 3 months, insiders sold 0 shares of Mirati Therapeutics Inc (MRTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 19,076 shares of Mirati Therapeutics Inc (MRTX) were sold and 2,528,737 shares were bought by its insiders, resulting in a net purchase of 2,509,661 shares.

Mirati Therapeutics Inc (MRTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Mirati Therapeutics Inc Insider Transactions

No Available Data

What does Vanda Pharmaceuticals Inc do?

Who are the key executives at Vanda Pharmaceuticals Inc?

Kevin C Tang is the 10 percent owner of Vanda Pharmaceuticals Inc. Other key executives at Vanda Pharmaceuticals Inc include VP & Acting CFO & Treasurer Kevin Patrick Moran , director & Chief Executive Officer Mihael Hristos Polymeropoulos , and SVP & General Counsel Timothy Williams .

Vanda Pharmaceuticals Inc (VNDA) Insider Trades Summary

Over the past 18 months, Kevin C Tang made no insider transaction in Vanda Pharmaceuticals Inc (VNDA). Other recent insider transactions involving Vanda Pharmaceuticals Inc (VNDA) include a net sale of 35,163 shares made by Kevin Patrick Moran , a net sale of 31,688 shares made by Timothy Williams , and a net sale of 20,451 shares made by Joakim Wijkstrom .

In summary, during the past 3 months, insiders sold 2,251 shares of Vanda Pharmaceuticals Inc (VNDA) in total and bought 0 shares, with a net sale of 2,251 shares. During the past 18 months, 166,385 shares of Vanda Pharmaceuticals Inc (VNDA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 166,385 shares.

Vanda Pharmaceuticals Inc (VNDA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Vanda Pharmaceuticals Inc Insider Transactions

No Available Data

What does Aradigm Corp do?

Who are the key executives at Aradigm Corp?

Kevin C Tang is the 10 percent owner of Aradigm Corp. Other key executives at Aradigm Corp include 10 percent owner Bleichroeder Lp , 10 percent owner First Eagle Investment Management, Llc , and 10 percent owner First Eagle Value In Biotechnology Master Fund, Ltd. .

Aradigm Corp (ARDMQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aradigm Corp (ARDMQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aradigm Corp (ARDMQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aradigm Corp (ARDMQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aradigm Corp Insider Transactions

No Available Data

What does Molecular Templates Inc do?

Who are the key executives at Molecular Templates Inc?

Kevin C Tang is the 10 percent owner of Molecular Templates Inc. Other key executives at Molecular Templates Inc include 10 percent owner Biotech Target N V , Chief Medical Officer Maurizio Voi , and CFO & Treasurer Sean Mclennan .

Molecular Templates Inc (MTEM) Insider Trades Summary

Over the past 18 months, Kevin C Tang made no insider transaction in Molecular Templates Inc (MTEM). Other recent insider transactions involving Molecular Templates Inc (MTEM) include a net purchase of 4,505,319 shares made by Biotech Target N V ,

In summary, during the past 3 months, insiders sold 0 shares of Molecular Templates Inc (MTEM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Molecular Templates Inc (MTEM) were sold and 533,688 shares were bought by its insiders, resulting in a net purchase of 533,688 shares.

Molecular Templates Inc (MTEM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Molecular Templates Inc Insider Transactions

No Available Data

What does Aptevo Therapeutics Inc do?

Who are the key executives at Aptevo Therapeutics Inc?

Kevin C Tang is the 10 percent owner of Aptevo Therapeutics Inc. Other key executives at Aptevo Therapeutics Inc include SVP & CFO Daphne Taylor , See Remarks Soyoung Kwon , and 10 percent owner Tang Capital Partners Lp .

Aptevo Therapeutics Inc (APVO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aptevo Therapeutics Inc (APVO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aptevo Therapeutics Inc (APVO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aptevo Therapeutics Inc (APVO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aptevo Therapeutics Inc Insider Transactions

No Available Data

What does Jounce Therapeutics Inc do?

Who are the key executives at Jounce Therapeutics Inc?

Kevin C Tang is the 10 percent owner of Jounce Therapeutics Inc. Other key executives at Jounce Therapeutics Inc include 10 percent owner Concentra Merger Sub, Inc. , 10 percent owner Concentra Biosciences, Llc , and director & CEO and President Richard /ca/ Murray .

Jounce Therapeutics Inc (JNCE) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Jounce Therapeutics Inc (JNCE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Jounce Therapeutics Inc (JNCE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Jounce Therapeutics Inc (JNCE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Jounce Therapeutics Inc Insider Transactions

No Available Data

What does TCR2 Therapeutics Inc do?

Who are the key executives at TCR2 Therapeutics Inc?

Kevin C Tang is the 10 percent owner of TCR2 Therapeutics Inc. Other key executives at TCR2 Therapeutics Inc include director & 10 percent owner Ansbert Gadicke , 10 percent owner Mpm Asset Management Llc , and 10 percent owner Tang Capital Management Llc .

TCR2 Therapeutics Inc (TCRR) Insider Trades Summary

Over the past 18 months, Kevin C Tang made 4 insider transaction in TCR2 Therapeutics Inc (TCRR) with a net purchase of 468,513. Other recent insider transactions involving TCR2 Therapeutics Inc (TCRR) include a net sale of 70,170 shares made by Mpm Asset Management Llc , a net sale of 70,170 shares made by Ansbert Gadicke ,

In summary, during the past 3 months, insiders sold 0 shares of TCR2 Therapeutics Inc (TCRR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 140,340 shares of TCR2 Therapeutics Inc (TCRR) were sold and 468,513 shares were bought by its insiders, resulting in a net purchase of 328,173 shares.

TCR2 Therapeutics Inc (TCRR)'s detailed insider trading history can be found in Insider Trading Tracker table.

TCR2 Therapeutics Inc Insider Transactions

No Available Data

What does Rain Oncology Inc do?

Who are the key executives at Rain Oncology Inc?

Kevin C Tang is the 10 percent owner of Rain Oncology Inc. Other key executives at Rain Oncology Inc include Principal Fin. & Acc. Officer Josephine Bruce , 10 percent owner Tang Capital Management Llc , and 10 percent owner Tang Capital Partners Lp .

Rain Oncology Inc (RAIN) Insider Trades Summary

Over the past 18 months, Kevin C Tang made 3 insider transaction in Rain Oncology Inc (RAIN) with a net purchase of 1,198,445. Other recent insider transactions involving Rain Oncology Inc (RAIN) include a net sale of 995,000 shares made by Boxer Capital, Llc ,

In summary, during the past 3 months, insiders sold 0 shares of Rain Oncology Inc (RAIN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,168,973 shares of Rain Oncology Inc (RAIN) were sold and 1,372,418 shares were bought by its insiders, resulting in a net purchase of 203,445 shares.

Rain Oncology Inc (RAIN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Rain Oncology Inc Insider Transactions

No Available Data

Kevin C Tang Mailing Address

Above is the net worth, insider trading, and ownership report for Kevin C Tang. You might contact Kevin C Tang via mailing address: 4747 Executive Drive, Suite 210, San Diego Ca 92121.

Discussions on Kevin C Tang

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.